Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2026)

Cytek Biosciences filings provide 6 years of Capital Expenditures readings, the most recent being $4.0 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 5026.92% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 2207.34% increase, with the full-year FY2025 number at $4.1 million, up 2207.34% from a year prior.
  • Capital Expenditures hit $4.0 million in Q4 2025 for Cytek Biosciences, up from -$2.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q4 2022 to a low of -$2.3 million in Q3 2025.
  • Median Capital Expenditures over the past 5 years was $505000.0 (2023), compared with a mean of $981947.4.
  • The widest YoY moves for Capital Expenditures: up 5026.92% in 2025, down 9654.17% in 2025.
  • Cytek Biosciences' Capital Expenditures stood at -$309000.0 in 2021, then surged by 2741.1% to $8.2 million in 2022, then tumbled by 81.62% to $1.5 million in 2023, then tumbled by 94.8% to $78000.0 in 2024, then soared by 5026.92% to $4.0 million in 2025.
  • The last three reported values for Capital Expenditures were $4.0 million (Q4 2025), -$2.3 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.